Trials / Unknown
UnknownNCT05313022
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 60 Years and Above
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZR-202-CoV | Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine |
| OTHER | Placebo | Normal saline solution |
Timeline
- Start date
- 2022-01-18
- Primary completion
- 2022-05-13
- Completion
- 2023-06-01
- First posted
- 2022-04-06
- Last updated
- 2023-04-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05313022. Inclusion in this directory is not an endorsement.